CHMP fandt det acceptabelt at fjerne denne kontraindikation, da den primære eliminationsvej for valsartan er biliær, og nyreclearance tegner sig for mindre end 30% af plasmaclearance.
The CHMP considered it acceptable to remove this contraindication, as the primary route of elimination of valsartan is via biliary route and renal clearance accounts for less than 30% of plasma clearance.